Yang Liu1, Hong-Xia Chen1, Dao-Lin Kang1, Xiao-Hua Kuang2, Wen-Xing Liu2, Jin Ni2. 1. Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College Nanchong, Sichuan, China. 2. Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University Guangzhou, P.R. China.
Abstract
OBJECTIVE: The purpose of our study was to observe the influence of dexmedetomidine on complications caused by hemabate in patients undergoing caesarean section. METHODS: A total of 120 females (age range, 20-40 years) at 35-40 weeks gestation who delivered by cesarean between September, 2014 and December, 2014 were enrolled in our study. Patients were randomly allocated into three groups that received intravenously physiological saline 20 mL (placebo group), lower dose (0.5 μg kg(-1)) of dexmedetomidine (low-dex gruop) and higher dose (1 μg kg(-1)) of dexmedetomidine (high-dex group) during cesarean section, following the delivery of the infant and intramuscular hemabate injection. RESULTS:Nausea, vomiting, chest congestion and elevated blood pressure were the most common adverse events of placebo group. Compared with placebo group, the above mentioned adverse reactions decreased significantly in both low-dex group and high-dex group (P<0.05), whereas there were no significant difference between low-dex group and high-dex group (P>0.05). As to patient satisfaction score, low-dex group and high-dex group were all higher than placebo group (P<0.05). Furthermore, there were more patients satisfied with high-dex group than low-dex group (P<0.05). CONCLUSION:Dexmedetomidine (0.5 μg kg(-1) and 1 μg kg(-1)) were all effective in preventing adverse reactions introduced by hemabate and improve parturients' satisfaction in patients undergoing cesarean delivery. And higher dose (1 μg kg(-1)) of dexmedetomidine is superior to lower dose (0.5 μg kg(-1)) in patient satisfaction.
RCT Entities:
OBJECTIVE: The purpose of our study was to observe the influence of dexmedetomidine on complications caused by hemabate in patients undergoing caesarean section. METHODS: A total of 120 females (age range, 20-40 years) at 35-40 weeks gestation who delivered by cesarean between September, 2014 and December, 2014 were enrolled in our study. Patients were randomly allocated into three groups that received intravenously physiological saline 20 mL (placebo group), lower dose (0.5 μg kg(-1)) of dexmedetomidine (low-dex gruop) and higher dose (1 μg kg(-1)) of dexmedetomidine (high-dex group) during cesarean section, following the delivery of the infant and intramuscular hemabate injection. RESULTS:Nausea, vomiting, chest congestion and elevated blood pressure were the most common adverse events of placebo group. Compared with placebo group, the above mentioned adverse reactions decreased significantly in both low-dex group and high-dex group (P<0.05), whereas there were no significant difference between low-dex group and high-dex group (P>0.05). As to patient satisfaction score, low-dex group and high-dex group were all higher than placebo group (P<0.05). Furthermore, there were more patients satisfied with high-dex group than low-dex group (P<0.05). CONCLUSION:Dexmedetomidine (0.5 μg kg(-1) and 1 μg kg(-1)) were all effective in preventing adverse reactions introduced by hemabate and improve parturients' satisfaction in patients undergoing cesarean delivery. And higher dose (1 μg kg(-1)) of dexmedetomidine is superior to lower dose (0.5 μg kg(-1)) in patient satisfaction.
Authors: P Talke; R Chen; B Thomas; A Aggarwall; A Gottlieb; P Thorborg; S Heard; A Cheung; S L Son; A Kallio Journal: Anesth Analg Date: 2000-04 Impact factor: 5.108
Authors: Islam M Massad; Wafa A Mohsen; Asma S Basha; Khaled R Al-Zaben; Mahmoud M Al-Mustafa; Subhi M Alghanem Journal: Saudi Med J Date: 2009-12 Impact factor: 1.484
Authors: James D Griffiths; Gillian Ml Gyte; Phil A Popham; Kacey Williams; Shantini Paranjothy; Hannah K Broughton; Heather C Brown; Jane Thomas Journal: Cochrane Database Syst Rev Date: 2021-05-18
Authors: Ioannis D Gallos; Helen M Williams; Malcolm J Price; Abi Merriel; Harold Gee; David Lissauer; Vidhya Moorthy; Aurelio Tobias; Jonathan J Deeks; Mariana Widmer; Özge Tunçalp; Ahmet Metin Gülmezoglu; G Justus Hofmeyr; Arri Coomarasamy Journal: Cochrane Database Syst Rev Date: 2018-04-25